So far, many molecular markers have already been put into clinical use in the diagnosis of BC, and the main tumor markers comprise glycoantigen 153, glycoantigen 125, carcinoembryonic antigen, and HER2, the expression of which is crucial in the treatment of BC (8, 9). The gene discussed is CEACAM5; the disease is neoplasm.